Extended Data Fig. 7: Loss or inhibition of QPCTL impairs monocyte migration.
a, Qpctl+/+ and Qpctl–/– littermates were inoculated with Qpctl+/+ or Qpctl–/– EO771 cells, respectively. Quantification of tumor-associated leukocytes (n = 6). *P = 0.009. b, Gating strategy to identify tumor-infiltrating WT CD45.1+ monocytes transferred into LL/2 tumor-bearing mice. c,d, WT mice received Ctrl vehicle or QPCTLi for 4 days before LL/2 or EO771 inoculation (preventative) or at day 7 after LL/2 inoculation (therapeutic). Quantification of c, splenic monocytes (n = 8 (LL/2 preventative), 8 (EO771 ctrl), 9 (EO771 QPCTLi), 10 (LL/2 Ctrl therapeutic) or 6 (LL/2 QPCTLi therapeutic)), *P = 0.02, **P = 0.004, ***P = 0.0002, and d, tumor-infiltrating macrophages (n = 8 (LL/2 preventative), 8 (EO771 Ctrl), 9 (EO771 QPCTLi), 10 (LL/2 Ctrl therapeutic) or 6 (LL/2 QPCTLi therapeutic)). NS, P > 0.05, *P = 0.01. e,f, WT mice treated with Ctrl Isotype or anti-CSF1R blocking antibody were inoculated with e, EO771 (n = 4), NS, P > 0.05, *P = 0.03 or f, LL/2 cells (n = 7 (Isotype) or 8 (anti-CSF1R)). NS, P > 0.05, *P = 0.0003. Quantification of leukocytes in tumors excised e, 14 days or f, 19 days after tumor cell inoculation. Bars are medians and symbols represent individual mice. Data shown are representative experiments. All experiments were repeated independently (≥ twice). Statistical analysis was done using unpaired, nonparametric Mann-Whitney U-test.
